Data / Form D filings / Genesis Therapeutics, Inc.
Genesis Therapeutics, Inc.: Form D filings
Genesis Therapeutics, Inc., a biotechnology company in Burlingame, CA, filed 3 Form D notices with the SEC between 2020 and 2023. The latest, on August 25, 2023, reports $224 million sold of a $224 million offering to 50 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1440 CHAPIN AVE, SUITE 385, Burlingame, CA, 94010
- Phone
- (203) 615-4567
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2019
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1775819
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 25, 2023 | New notice | $224,025,681 | $224,025,681 | 50 | Aug 10, 2023 | sec.gov | |
| Dec 23, 2022 | New notice | $23,894,572 | $23,894,572 | 33 | Jun 22, 2022 | sec.gov | |
| Dec 9, 2020 | New notice | Indefinite | $49,517,631 | 24 | Nov 24, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| VIJAY PANDE | Director | |
| EVAN FEINBERG | Executive Officer, Director | |
| PEPTIBOON PRASIT | Executive Officer, Director | |
| WILLIAM MCCARTHY | Executive Officer | |
| LEONARD BELL | Director | |
| KRIS JENNER | Director | |
| BENJAMIN SKLAROFF | Executive Officer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Aug 21, 2023 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Genesis Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.